病例报告：从人类白细胞抗原匹配的活体亲属供体进行同种异体单纯角膜缘上皮移植治疗准分子激光原位角膜磨镶术后双侧角膜化学伤
Case Report: Allogenic Simple Limbal Epithelial Transplantation From a Human Leukocyte Antigen-Matched Living Related Donor to Treat Bilateral Corneal Chemical Burns Post Laser-Assisted Keratomileusis.
作者信息
Chang Yuh-Shin, Chan Tsung-Yueh, Jan Ren-Long, Tseng Sung-Huei
机构信息
Department of Ophthalmology, Chi Mei Medical Center, Tainan, Taiwan.
Graduate Institute of Medical Science, College of Health Science, Chang Jung Christian University, Tainan, Taiwan.
出版信息
Front Med (Lausanne). 2022 Feb 25;9:849791. doi: 10.3389/fmed.2022.849791. eCollection 2022.
A 35-year-old woman who had undergone laser-assisted keratomileusis in both eyes experienced bilateral total limbal stem cell deficiency (LSCD) due to chemical burns. Due to bilateral severe LSCD, allogenic simple limbal epithelial transplantation (SLET) from a human leukocyte antigen (HLA)-matched living related donor was the first choice of treatment for her left eye. We report the first case of HLA or ABO matching living related allogenic SLET for permanent restoration of the cornea for bilateral LSCD treatment. Our ABO-HLA-matched living related allogenic SLET alleviation of the systemic immunosuppressant to topical corticosteroids alone. It also came the limitations of prolonged systemic immunosuppressant usage in conjunctival-limbal allografts and keratolimbal allograft.
一名35岁女性双眼接受过准分子激光原位角膜磨镶术，因化学烧伤导致双侧全角膜缘干细胞缺乏（LSCD）。由于双侧严重LSCD，来自人类白细胞抗原（HLA）匹配的活体亲属供体的同种异体单纯角膜缘上皮移植（SLET）是其左眼的首选治疗方法。我们报告了首例HLA或ABO匹配的活体亲属同种异体SLET用于双侧LSCD治疗并永久恢复角膜的病例。我们的ABO - HLA匹配的活体亲属同种异体SLET将全身免疫抑制剂减少至仅局部使用皮质类固醇。这也避免了在结膜角膜缘同种异体移植和角膜缘同种异体移植中长期使用全身免疫抑制剂的局限性。
Zotero 插件